Results 31 to 40 of about 238 (77)

Tumor methylation subtypes and their associated immune contextures predict the clinical outcome to ICI therapy of pleural mesothelioma patients: the NIBIT-EPI-MESO study

open access: yes
Pleural mesothelioma (PM) is an aggressive cancer with a dismal prognosis. Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1, the new standard of care for PM, is still clinically unsatisfying, regardless of PM histotype.
Anichini, Andrea   +29 more
core   +1 more source

The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? [PDF]

open access: yes
The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council, included a focus on the future of ...
Fox, Bernard   +8 more
core   +3 more sources

The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes

open access: yes
LBA2512 Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly showed that the hypomethylating agent (HMA) guadecitabine (guade), a prodrug of decitabine (D), followed by ipilimumab (I) was safe with promising clinical and ...
Rana, Ramiz   +19 more
core   +1 more source

A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study.

open access: yes, 2016
Background: Epigenetic alterations affect virtually all cellular pathways associated with tumorigenesis and cancer progression. Importantly, the multifaceted immunomodulatory activity of DHA has been shown to improve the immunogenicity and immune ...
Diana Giannarelli   +9 more
core   +1 more source

Intracranic injection of CIITA-driven MHC-II positive glioblastoma cells induces an effective anti-tumor immune response in vivo: implication for new therapeutic strategies against the glioblastoma

open access: yes, 2022
Background: Glioblastoma (GBM) is the most aggressive brain tumor with dismal prognosis despite standard of care including surgery, radiotherapy, and chemotherapy.
Accolla RS   +8 more
core   +1 more source

MA05.07 Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study [PDF]

open access: yesJournal of Thoracic Oncology, 2019
L. Calabro'   +9 more
openaire   +1 more source

Tumor recognition and acquisition of protecting adaptive anti-tumor immune response in vivo against CIITA-driven MHC class II expressing Oral Squamous Cell Carcinoma Cells

open access: yes, 2022
Background: We have previously demonstrated that cells from MHC class II-negative solid tumors can function as surrogate Antigen Presenting Cells (APCs) for their own tumor antigens, provided they optimally express MHC class II (MHC-II) molecules as a ...
Accolla RS   +5 more
core  

Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy [PDF]

open access: yesCancer Immunology, Immunotherapy, 2021
Bellone, Matteo   +11 more
openaire   +4 more sources

Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy

open access: yes
Melanoma plasticity drives immune evasion and therapy resistance through dynamic cell-state transitions beyond genetic alterations. Although epigenetic remodeling is central to this process, its impact under therapeutic pressure remains unclear.
Ceccarelli, Francesco   +3 more
core   +1 more source

INfluenza Vaccine Indication During anticancer therapy with Immune-checkpoint inhibitors: a transversal challenge for patient’s counselling – preliminary analysis of the retrospective, multicenter, INVIDIa study

open access: yes, 2017
Background Split vaccines are allowed during anticancer immunotherapy with immune-checkpoint inhibitors (CKI) and influenza vaccine is recommended in cancer patients.
Verzoni E   +35 more
core  

Home - About - Disclaimer - Privacy